Actual questions of diagnosis and treatment of idiopathic short stature in children

1Samson, OYa., 2Sprynchuk, NA, 2Bolshova, OV
1V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv; P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv
2V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv
Dopov. Nac. akad. nauk Ukr. 2017, 4:96-102
https://doi.org/10.15407/dopovidi2017.04.096
Section: Medicine
Language: Ukrainian
Abstract: 

Among all patients with short stature, the examination revealed the normal content of growth hormone (basal and stimulated levels) and reduced or normal levels of insulin-like growth factor-I in the majority, which automatically excludes these patients from a cohort of growth hormone deficiency. The vast majority of these patients had a diagnosis of idiopathic short stature; sometimes, there were isolated cases of a syndrome of biologically inactive growth hormone. The article discusses the diagnostic differences between these states and therapeutic interventions, by predicting the effectiveness of treatment.
Keywords: growth hormone, short stature, test of stimulation of insulin-like growth factor-I
References: 
  1. Wit, J. M. (2015). Idiopathic Short Stature. J. Clin. Res. Pediatr. Endocrinol., 7, Suppl. 1, pp. 2-2.
  2. Radovick, S. & MacGillivaray, M. N. (Eds.) (2013). Pediatric Endocrinology: A Practical Clinical Guide, 2nd ed. Totowa, NY: Humana press. https://doi.org/10.1007/978-1-60761-395-4
  3. Hermanussen, M. & Cole, J. (2003). The calculation of target height reconsidered. Horm. Res., 59, pp. 180-183. https://doi.org/10.1159/000069321
  4. Shandin, A., Nagaeva, E., Peterkova, V. & Dedov, I. (2010). The efficacy and safety of recombinant growth hormone in children with idiopathic short stature (two-year experience). Probl. endokrinologii, 56, No 6, pp. 14-23 (in Russian). https://doi.org/10.14341/probl201056614-23
  5. Visser-van Balen, H., Geenen, R., Kamp, G. A. & Sinnema, L. G. (2007). Long-term psychosocial consequences of hormone treatment for short stature. Acta Paediatr., 96, pp. 715-719. https://doi.org/10.1111/j.1651-2227.2007.00235.x
  6. Allen, D. B. & Fost, N. C. (2004). Growth hormone for short stature: ethical issues raised by expanded access. J. Pediatr., 144, pp. 648-652. https://doi.org/10.1016/j.jpeds.2004.02.028
  7. Sprynchuk, N. & Samson, O. (2010). Clinical features and treatment of syndrome of biological inactive growth hormone. Klinichna endokrynologiia ta endokrynna khirurgiia, No. 30, pp. 58-62 (in Ukrainian).